research forum XX Deck
SIR Foundation grantee spotlight: Govind Srimathveeravalli, PhD
SIR Foundation’s grant program is central to our mission of fostering innovation and research in IR. Through our grantees’ pioneering ideas and hard work, the research will lead to improved patient care and overall higher quality of life. In this grantee spotlight, Govind Srimathveeravalli, PhD, a biomedical engineer at Memorial Sloan Kettering Cancer Center and a 2016 recipient of the Dr. Ernest J. Ring Academic Development Grant, shares what inspired him to enter IR research, the impact SIR Foundation's support has made, and where he hopes is research will lead.
What inspired you to get into IR research? I was working in a start-up company developing new tools for robot-assisted surgery. I was looking to get back to academic research and had the opportunity to do a postdoctoral IR fellowship with Stephen B. Solomon, MD, FSIR, emphasizing image-guided cancer therapy. I felt this was a logical progression of my research as IR promises even less-invasive therapy of cancer when compared to robotic surgery, while creating interesting opportunities for studying the biological response of cancer to treatment (which is entirely absent following surgery). Because my training was largely in engineering, I had a steep learning curve. Fortunately, I received exceptional mentorship from Dr. Solomon and Joseph P. Erinjeri, MD, PhD, who were instrumental in initiating me in the field and guiding me through my early years.
How will SIR Foundation’s support further your research at this point in your career? The Ring Grant I received from SIR Foundation was my first sizeable grant
28 IRQ | WINTER 2019
as an independent principal investigator. Receiving funding to pursue your research interest provides a huge boost of confidence. It affirms others’ belief in your research and willingness to invest money in your development as a researcher. This recognition of your work also signals the value of your research to your peers.
Besides direct funding support, SIR Foundation provided me with a valuable peer network, especially the Research Grants and Education Division, whose members (mainly Erik N.K. Cressman, MD, PhD, FSIR, and Michael Borrelli, PhD) gave me encouragement, guidance and grant templates that helped me seek additional funding. SIR Foundation’s initial seed money and support has also helped to secure larger grants from the National Cancer Institute (NCI) and the Department of Defense (DOD).
What is your research studying? IRs use nonionizing energy to ablate tumors. Historically the emphasis has been to develop “stronger” medicine that can completely eradicate the tumor following a single ablation. Until the advent of immunotherapy, there was little interest in leveraging what happens at the ablation site into better treatments.
After studying the biological response of cancer to non-ionizing energy (mostly electric fields), I design image- guided techniques for cancer therapy, emphasizing targeted treatment, function preservation and improved locoregional control. Near-term translational potential is the key consideration in my research.
How do you perceive your research’s potential impact? IR’s role in cancer therapy has rapidly grown in the last few years but is
still restricted to the treatment of tumors in solid organs and soft tissue. My research will advance IR to tubular organs, locations where current therapies are inadequate. Surgery or radiation of a tumor in the genitourinary, gastrointestinal or respiratory tract results in loss of function and reduces the quality of life for patients. There is significant treatment-associated morbidity.
IR is uniquely positioned to treat these patients while preserving their quality of life, but suitable ablation tools and a better understanding of biology are critical components to advancing this vision. My lab develops devices and ablation techniques that are especially designed to safely (but completely) treat tumors in hollow organs.
SIR Foundation’s support has allowed us to study the biological activity at the site of ablation, allowing us to identify adjuvant techniques that improve the safety and efficacy of these treatments. Hopefully our findings in the lab will be translated by IRs to patient benefit in the short term.
What did you find most challenging about the grant writing process? Trying to figure out how to get unknown reviewers as excited about an idea as I am. I am writing the grant application because I have come upon a scientific question whose answer could change patients’ lives. Furthermore, I have figured out how to obtain that answer— and that’s exciting to me. The challenge I then face is how to effectively communicate this idea to someone else and get them sufficiently invested in it to recommend my grant for funding.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
